CRISPR Recovery? “Furor” Briefly Snips $500M From Companies’ Values – Xconomy
Undark Magazine |
CRISPR Recovery? “Furor” Briefly Snips $500M From Companies’ Values
Xconomy Is the J.P. Morgan CRISPR rollercoaster ride over? As rain fell heavily in San Francisco Monday, the first day of the massive healthcare conference, biotech stocks did, too. At least three of the companies getting drenched could blame a research paper … New Challenges May Lie Ahead for Use of CRISPR in HumansUndark Magazine Resistance to Common Germs Poses a Hurdle to New Gene TherapiesScientific American |
FierceBiotech |
Forty Seven lines up Roche as second partner for CD47 cancer immunotherapy
FierceBiotech Forty Seven has added Roche to its partner list for CD47-targeted immuno-oncology candidate, with Roche’s Genentech unit agreeing to sponsor two trials of the antibody in combination with its PD-L1 inhibitor Tecentriq. It’s the second I-O partnership … |
Medical Xpress |
How can CRISPR genome editing shape the future of cancer research?
Medical Xpress CRISPR allows scientists to precisely tweak genes faster than ever before, and at a fraction of the cost of older techniques. These tweaks can be used to answer questions in the lab, but there’s also excitement, and trepidation, over the potential use … |
BSA bureau (press release) |
New Challenges May Lie Ahead for Use of CRISPR in Humans
Undark Magazine In response to the frenzied reaction, the study’s lead author and other outside researchers clarified that the findings do not constitute a blow to CRISPR — just a factor that should be considered and studied further. Three of the top companies … Resistance to Common Germs Poses a Hurdle to New Gene TherapiesScientific American Immunity to CRISPR Gene Editing poses a challenge, says a researchBSA bureau (press release) |
Medical Xpress |
New immunotherapy approach boosts body’s ability to destroy cancer cells
Medical Xpress The compound is being evaluated on its own and also in combination with another type of immunotherapy drug called a PD-1 inhibitor. The Cell paper reports early findings from that trial for the first six patients, which showed that people who received … |
Genetic Engineering & Biotechnology News |
MilliporeSigma CEO Eyes New Technologies, Simpler Process for CAR–T Manufacturing
Genetic Engineering & Biotechnology News “The full supply chain is extremely difficult, to say the least. And we have to work together to simplify it,” Dr. Batra told GEN. The supply chain requires coordination between a patient’s primary oncology team and the manufacturing facility where the … |